Ouvrages publiés en collaboration (1)
  1. 1. Taton, O., Bondue, B., & Roufosse, F. (2022). Hypereosinophilic syndromes and lung involvement.
    2.   Parties d'ouvrages collectifs (9)
  2. 1. Gelfand, E. E., Simon, D., Simon, H.-U., Thomas, P. A., Busse, W. W., Nair, P., Gauvreau, G. G., Denburg, J. J., Bivins-Smith, E. E., Jacoby, D., Davis, B. B., Rothenberg, M., Khoury, P., Klion, A., Lotfi, R., Spada, N., Lotze, M. T., Schleimer, R. R., Kato, A., Kern, R., Lavigne, M. M., Eppihimer, M. M., Roufosse, F., Le Moine, A., Massart, A., Benghiat, F., Lemaitre, P., Krahn, M., Bartoli, M., & Levy, N. (2013). Eosinophils in Human Disease. In Eosinophils in Health and Disease (pp. 431-536). Elsevier Inc. doi:10.1016/B978-0-12-394385-9.00013-4
  3. 2. Roufosse, F., Massart, A., Benghiat, F., Lemaitre, P., & Le Moine, A. (2012). Eosinophils and Allograft Rejection. In J. L. Lee & H. F. Rosenberg (Eds.), Eosinophils in Health and Disease. Academic Press, Elsevier.
  4. 3. Roufosse, F., Goldman, M., Cogan, E., & Lottenberg, R. (2009). Hypereosinophilia: Primary and Secondary. In Evidence-Based Hematology (pp. 221-228). John Wiley and Sons. doi:10.1002/9781444300857.ch27
  5. 4. Roufosse, F., Goldman, M., & Cogan, E. (2009). Hypereosinophilic syndromes. In Urticaria and Angioedema. Informa Healthcare publishers.
  6. 5. Roufosse, F., Klion, A. D., & Weller, P. F. (2009). Treatment of the hypereosinophilic syndromes. In UpToDate. Waltham, MA: UpToDate, Basow, DS.
  7. 6. Roufosse, F., Klion, A. D., & Weller, P. F. (2009). Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes. In UpToDate. Waltham, MA: UpToDate, Basow, DS.
  8. 7. Roufosse, F., Goldman, M., & Cogan, E. (2008). Hyperesoinophilia: primary and secondary. In Evidence Based Hematology. Blackwell Publishers.
  9. 8. Roufosse, F., Goldman, M., & Cogan, E. (2004). Idiopathic hypereosinophilic syndrome. In Orphanet Encyclopedia (pp. 1-7).
  10. 9. Goldman, M., Bartholomé, E., & Roufosse, F. (2000). Mechanisms of action and clinical uses of type-I interferons. In A. Mantovani & P. Ghezzi (Eds.), Pharmacology of Cytokines (pp. 279-318). Oxford University press.
    11.   Articles dans des revues avec comité de lecture (90)
  11. 1. Ogbogu, P. U., Roufosse, F., Akuthota, P., Kuna, P., Groh, M., Reiter, A., Yokota, A., Siddiqui, S., Mutsaers, P. P., Li, B., Khoury, P., Bahadori, L. L., Bednarczyk, A., Bouma, G., Brooks, L., Ferreira, J., Grindebacke, H., Ho, C. C., Jain, P., Palmer, R. R., Jison, M., & Klion, A. (2026). Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nature medicine, 32(6), 2319. doi:10.1038/s41591-026-04315-8
  12. 2. Catherine, J., Karimi, S., Dewispelaere, L., Lelubre, C., Schandené, L., & Roufosse, F. (2025). Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A multicenter prospective study. Journal of allergy and clinical immunology. doi:10.1016/j.jaci.2024.12.1085
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>